The new advances of radionuclide ⁸⁹Sr in metastatic bone cancer

Bone pain from metastatic disease is the most common in cancers of the breast, prostate, and lung. Patients, with disseminated, hormone-refractory or chemo-refractory cancer suffered from persisting bone pain, can get benefet from ⁸⁹Sr. Radionuclide ⁸⁹Sr, a kind of new theraphy and saltly for metastatic bone cancer.Beta-emitting of ⁸⁹Sr, bone-seeking radiopharmaceuticals, concentrate in painful bone lesions,including those that can not be seen by X-ray, CT or MRI. Absorbing of ⁸⁹Sr by lesions selectively can diminish the radiation dose of normal tissue and highten curative effect.Multicentre observational study proved that has been effective in providing pain relief for metastatic bone cancer with a total response rate of more than 80%, and it's side effects were generally mild. Radionuclide ⁸⁹Sr together with external beam radiotheraphy or chemotheraphy can bring patients a significant improvement in pain palliation and a cytostatic effect on bone lesions, cut down the side effect and then can also prolong patients survival effectively.